Breaking News

Halozyme, argenx Expand Exclusive ENHANZE Agreement

argenx nominates four new targets for Halozyme's ENHANZE drug delivery technology.

Halozyme Therapeutics, Inc. announced that argenx has nominated four new targets under its global collaboration and license agreement that provides argenx exclusive access to Halozyme’s ENHANZE drug delivery technology, a recombinant human hyaluronidase PH20 enzyme (rHuPH20) for rapid subcutaneous drug delivery. argenx, a global immunology company, now has exclusively licensed ENHANZE for a total of six targets, including for the neonatal Fc receptor (FcRn) target. 
 
VYVGART Hytrulo, argenx’s branded FcRn blocker, is approved by the U.S. FDA for chronic inflammatory demyelinating polyneuropathy and generalized myasthenia gravis, with additional approvals granted in more than 25 countries globally for the latter indication.
 
Under the expanded agreement, argenx will make upfront payments of $7.5 million per target nomination for a total of $30 million to Halozyme, and potential future milestone payments related to development progress, regulatory approvals, and sales attainment of up to $85 million per nominated target. Halozyme is also eligible to receive royalties.
 
“We are very pleased to strengthen our relationship with argenx, an innovative leader in immunology dedicated to improving the lives of people suffering from severe autoimmune diseases. As the leader in rapid subcutaneous drug delivery, ENHANZE has clinically demonstrated shorter administration time, offering patients and healthcare practitioners with more convenience and flexibility in how therapies are delivered,” said Dr. Helen Torley, president and chief executive officer.”
 
Tim Van Hauwermeiren, Chief Executive Officer of argenx, added, “We are very excited to have access to Halozyme’s leading subcutaneous delivery technology now for six different targets. The expansion of our exclusive access to ENHANZE plays a critical role in solidifying our leadership position and delivering on our commitment to providing life-changing immunology solutions to patients.”

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters